Program
mRNA-1345 respiratory syncytial virus vaccine
Its studies are mostly in Virus Diseases · Coronavirus Infections · Influenza, Human, led by Moderna.
Drug pageMRNA-1345 respiratory syncytial virus vaccine: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Nov 9, 202111 company-led studies, 1 open or runningNext primary completion: Aug 31, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 111 open or running | phase 3since Nov 9, 2021 | Aug 20, 2020 | Aug 31, 2029phase 1 · NCT05743881 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2020First study: phase 1 study in Virus DiseasesFirst studyNCT04528719 · 651 enrolled · United States
- Nov 9, 2021Phase 3 study in Virus DiseasesNCT05127434 · 36,814 enrolled · United States, Argentina, Australia and more
- Apr 8, 2022Phase 3 study in Virus DiseasesNCT05330975 · 3,317 enrolled · United States
- May 25, 2022Phase 1 study in Coronavirus InfectionsNCT05397223 · 308 enrolled · United States
- Oct 14, 2022Phase 1 study in Influenza, HumanNCT05585632 · 392 enrolled · United States, Australia, United Kingdom
- Feb 15, 2023Phase 1 study in Respiratory Syncytial VirusNCT05743881 · 186 enrolled · United States, Panama, United Kingdom
- Sep 23, 20232 phase 3 studies in Virus DiseasesNCT06060457, NCT06067230
- Oct 18, 2023Phase 2 study in Virus DiseasesNCT06097299 · 349 enrolled · United States, Panama
- Nov 14, 2023Phase 2 study in Virus DiseasesNCT06143046 · 360 enrolled · United States, Canada, Chile and more
- Aug 5, 2025Phase 3 study in Virus DiseasesNCT07117487 · 507 enrolled · United States
Ahead
- Aug 31, 2029Primary completion: phase 1 study in Respiratory Syncytial VirusNCT05743881
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07117487Virus Diseases · United States | 3 | Completed | Mar 27, 2026 | 507 |
| NCT06143046Virus Diseases · United States, Canada, Chile and more | 2 | Completed | May 25, 2026 | 360 |
| NCT06097299Virus Diseases · United States, Panama | 2 | Completed | Jun 27, 2025 | 349 |
| NCT06067230Virus Diseases · United States, Canada, Puerto Rico and more | 3 | Completed | Jul 24, 2026 | 1,153 |
| NCT06060457Virus Diseases · United States | 3 | Completed | Jun 7, 2024 | 1,900 |
| NCT05743881Respiratory Syncytial Virus · United States, Panama, United Kingdom | 1 | Active, not recruiting | Aug 31, 2029 | 186 |
| NCT05585632Influenza, Human · United States, Australia, United Kingdom | 1 | Completed | Feb 28, 2024 | 392 |
| NCT05397223Coronavirus Infections · United States | 1 | Completed | Feb 27, 2026 | 308 |
| NCT05330975Virus Diseases · United States | 3 | Completed | Nov 8, 2024 | 3,317 |
| NCT05127434Virus Diseases · United States, Argentina, Australia and more | 3 | Completed | Jul 28, 2025 | 36,814 |
| NCT04528719Virus Diseases · United States | 1 | Completed | Jul 18, 2024 | 651 |
How it is read
Names in the registry
- “mRNA-1345”, 11 entries
Conditions, from the studies’ own filings
- Virus Diseases, 8 studies
- Coronavirus Infections, 1 study
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.